Week 2- Obstructive Airway Diseases (asthma And COPD) Flashcards

1
Q

Define asthma

A

Asthma is defined as recurrent and reversible airways obstruction characterised by wheeze, SOB and nocturnal cough. Severe attack’s cause hypoxaemia and are life threatening.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the aetiology of asthma?

A

Genetic factors Environmental factors Acute triggers- allergens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Give examples of the factors involved in the aetiology of asthma

A

Genetics Acute triggers: dust/ mould/pollen/pet hair Environmental factors: Cold air Exercise Emotion Drugs Viral infections Atmospheric pollution Occupational sensitisers- wood/latex/dust Irritant vapours- cigarette fumes/ perfume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the two types of asthma? Outline their differences

A

Extrinsic/ atopic: Typical onset childhood

Associated with atopy- genetic predisposition to amount an exaggerated inappropriate immune response to an allergen, associated with hay fever and eczema.

Has both sensitisation and effector phases

Intrinsic/ non atopic:

Typical onset middle age

Often after an upper respiratory infection

No personal or family history of asthma or atopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Give three things asthma is characterised by

A
  1. Reversible airways obstruction
  2. Bronchial hyper responsiveness
  3. Airways inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the histological changes seen in an asthmatic bronchus

A
  • Mucus plug formation formed by an increase in the number of goblet cells and submucosal gland hypertrophy.
  • Loss of and damage to the respiratory epithelium, exposure of nerve fibres
  • Basement Membrane thickening
  • Bronchial smooth muscle hypertrophy and hyperplasia
  • Chronic inflammation with infiltration of macrophages/ eosinophils/ neutrophils/ mast cells/ Th2 cells in the lamina propria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the early phase of asthma development

A
  • Exposure to an allergen
  • Presentation of the allergen by an antigen presenting cell/APC
  • APC activates Th2 cells which start to produce inflammatory cytokines (IL3/5)
  • Inflammatory cytokines attracts other inflammatory cells by chemotaxis, especially eosinophils which are stimulated to activate/ differentiate and start releasing these granule contents.
  • Eosinophils release leukotrienes- potent bronchoconstrictors and lipid signalling molecule
  • Eosinophils release toxic granule proteins which damage respiratory epithelium and expose nerve fibres leading to airways hyperresponsiveness.
  • Inflammatory cytokine release from Th2 cell stimulates B plasma cells to make and release IgE.
  • Cytokines from Th2 cell also stimulate mast cells to express IgE receptors on their surface
  • Next exposure to allergen causes IgE crosslinking and degranulation of mast cells
  • Mast cells release leukotrienes and histamine- potent bronchoconstrictors.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What happens in atopic asthma that produces a specific response?

A
  • In atopic/ extrinsic asthma B cells produce allergen specific IgE
  • This means upon next exposure of this allergen there will be a specific response to that allergen by crosslinking of IgE on mast cells and degranulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Give two powerful bronchoconstrictors

A
  1. Leukotrienes
  2. Histamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What cell does a mast cell come from?

A
  • A mast cell is an immature form of basophil and only matures once it reaches its tissue site
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the late phase of asthma development and chronic remodelling

A
  • Progressing inflammatory reaction set up by early phase inflammatory cell infilitration and production of proinflammatory cytokines (IL’s)
  • Continued infiltration by Th2 cells/ eosinophils by chemotaxis
  • Eosinophil release of leukotriene and toxic granular proteins
  • Damage to respiratory epithelium and exposure of sensory and cholinergic fibres. These sensory nerves can be activated by inflammatory mediators leading to cholinergic reflex- SMC contraction. =Bronchial hyperresponsivenness.
  • Growth factor release from inflammatory cells leads to smooth muscle cell hypertrophy and hyperplasia
  • Stimulates increase in number of goblet cells and submucosal gland hyperplasia- increase in mucus production and formation of mucus plug.
  • BM thickening
  • Rexposure to allergen and crosslinking of IgE on mast cells releasing histamine/leukotriene leads to bronchoconstriction and increased vascular permeability.
  • Increased vascular permeability leads to oedema.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Is chronic airways remodelling in asthma reversible?

A
  • No, once the chronic inflammatory changes have occured this is irreversible.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What investigation allows you to swiftly assess severity of asthma?

A

Peak flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe signs and symptoms of asthma

A
  • Chronic inflammatory condition with acute exacerbations - “Asthma Attack” after trigger
  • Diurnal variation- often worse at night/ morning dipping with improvement throughout the day
  • Cough
  • Wheeze - expiratory due to turbulent flow via reduce lumen
  • Tight chest
  • SOB
  • Closely associated with atopy- hayfever/ ecezma/ hives/allergic rhinitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe signs of an acute asthma exacerbation/ attack

A
  • Difficultly completing sentences in 1 breath
  • Wheeze/ Cough/ SOB/ Chest tightness
  • Tachypnoea
  • Tachycardia
  • Accessory muscle use
  • Reduced breath sounds when severe
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How would you diagnose asthma?

A
  • In a strongly suspected patient give a course of treatment and see if there is any improvement
  • In a moderately suspected patient asses via spirometry before and after a small dose of histamine and then salbutamol.
  • If there is a response- diagnosis= asthma
  • No response likely differential diagnosis- SOB/ wheeze can be caused by HF/ Lung CA.
17
Q

Non pharmacological method of treating asthma?

A
  • Oxygen until saturation is 94-96%
18
Q

How does the remodelling stage occur in asthma?

A
  • Infiltration of fibroblasts
  • Fibroblasts fibrose chronically inflamed tissue
  • Lumen narrows and becomes less compliant
  • Patient has reduced inspiratory flow rate as a result
19
Q

What are the severities of asthma?

What are the factors involved in assessing asthma severity?

A
  • Moderate acute asthma -
    • PEF 50-75% of predicted or best
    • worsening symptoms
    • no symptoms of severe acute asthma
  • Severe acute asthma-
    • PEF 33-50% of best
    • RR above or equal to 25
    • HR above or equal to 110 bpm
    • Difficulty completing sentences in 1 breath
  • Life threating asthma:
    • ​PEF under 33%
    • PaO2 under 8kpa
    • PaCO2 normal (4- 6.0kPa)- patient is hyperventilating due to bronchoconstriction and low oxygen- blow off more CO2 despite reduced overall ventilation
    • Also altered conciousness/ silent chest/ poor resp effort/ cyanosis/ arrythmia/ hypotension
  • Near fatal asthma:
    • ​​​All of the above but raised PaCO2- above 6.0kPa, mechanical ventilation required
20
Q

Describe the management of acute asthma

A
  • Oxygen until sats 94-96%
  • Bronchodilators: B2 adrenergic agonists:
    • Terbutaline or salbutamol
    • Via inhaled nebuliser repeat 15/30 mins
    • Severe cases IV salbutamol
  • Antiinflammatory agents: Corticosteroids:
    • Prednisilone or hydrocortisone
    • downregulate transcription of proinflammatory genes
    • Continued for 5 days
  • Anticholinergics for poor bronchodilator response:
    • Tiotroprium bromide or ipratroprium bromide
  • Magnesium sulphate- direct bronchodilator used in acute severe asthma/life-threatening/near-fatal asthma with poor response
21
Q

Asthma treatment:

When would you use magnesium sulphate?

When would you used antibiotics?

A

Direct bronchodilator used in acute severe asthma/ life threatening/ near fatal asthma with poor response

Antibiotics- Only in the presence of infection

22
Q

Define COPD

What is it an umbrella term for?

How is it diagnosed normally?

What can support a diagnosis?

A
  • COPD = chronic obstructive pulmonary disease. It is lung disease characterised by chronic obstruction of airflow that interferes with normal breathing and is usually irreversible.
  • Umbrella term for both chronic bronchitis and emphysema.
  • Diagnosed via spirometry, supportive of diagnosis is low peak expiratory flow and classical symptoms:
    • ​Productive cough for years preceding
    • SOB/ Dysponea
23
Q

Describe the pathophysiology of Chronic Bronchitis

A
  • Exposure of cigarette smoke/ pollutants leads to irritation of bronchial airway lining
  • Activation of the innate and adaptive immune systems
  • Infiltration of bronchial respiratory epithelium by Neutrophils, macrophages and T lymphocytes (Th 1 and Th2).
  • Release of cytokines and proinflammatory mediators (eg interleukins) and oxidative stress
  • Stimulation of mucosal gland metaplasia- submucosal gland hypertrophy and increase in goblet cells
  • Hypersecretion of mucus and plug formation
  • Inflammatory cytokines leads to vasodilation and oedema
  • oedema and mucus overproduction reduces cilia motility
  • reduced clearance of mucus leads to increased susceptibility to infections
  • Bronchi become clogged
  • Recurrent infection leads to further inflammation
24
Q

What are the cardinal symptoms for COPD?

What are less common symptoms?

A
  • Dysponea / SOB
  • Chronic Cough
  • Sputum production
  • Frequent infective exacerbations with purulent sputum
  • Respiratory failure signs (hypoxia and hypercapnia)

Less common symptoms:

  • Chest tightness
  • Wheeze
25
Q

What are the risk factors for COPD?

A
  • Smoking (95% cases) and cannabis smoking
  • Genetics ( not all smokers develop COPD)- alpha 1 anti trypsin deficiency
  • Recurrent lung infections
  • Air pollution
  • Low birth weight
  • Low socioeconomic status
26
Q

What three diseases does COPD encompass?

A
  1. Chronic asthma
  2. Chronic bronchitis- Blue bloaters
  3. Emphysema- Pink puffers
27
Q

What three things characterise emphysema?

what three things characterise chronic bronchitis?

A

Emphysema:

  • Small airways - lobules and alveoli
  • Air space enlargement
  • Alveolar wall destruction

Chronic Bronchitis:

  • Affects larger airways- Bronchi and bronchioles
  • Mucus gand hypertrophy and hyperplasia
  • Hypersecretion of mucus
28
Q

Describe the pathophysiology of Emphysema

A
  • Exposure of cigarette smoke/ air pollutants
  • Activates macrophages that normally reside in the alveolus which protect against infection
  • Activated macrophages release proinflammatory cytokines
  • Recruits neutrophils from the pulmonary circulation to the alveolus
  • Neutrophil releases proteases- particularly elastase which breaks down elastin
  • Loss of elastic recoil- air trapping and hypoventilation
  • Leads to hypoxaemia and hypercapnia
  • Oxidative stress due to cigarette smoke and oxygen free radicals released by inflammatory cells.
  • Leads to increased apoptosis of alveolar pneumocytes.
  • Inflammatory cell infiltration, release of cytokines, proteases and oxidative free radicals leads to destruction of alveolar walls and pulmonary capillaries.
  • Reduction in both ventilation and perfusion leads to a matched V/Q defecit.
29
Q

Outline the gross pathology of Chronic Bronchitis- The Blue Bloater

How can this affect the cardiovascular system?

A
  • Exposure to smoking/ pollutants activates the immune system
  • Invasion by macrophages, T lymphocytes and neutrophils, production of proinflammatory cytokines
  • Stimulation of mucosal gland hypertrophy and hyperplasia
  • Increase in goblet cell number and secretions
  • Mucus hypersecretion
  • Cytokines increase vasodilation and oedema
  • Both oedema and mucus reduce cilia motility- reduced mucus clearance
  • Increased infections and inflammation leads to:
  • Bronchoconstriction and airways obstruction
  • Airways obstruction leads to hypoventilation of alveoli:
    • Reduced PAO2 in alveolus and increased PACO2 in alveolus. Therefore increases PaCO2 and decreases PaO2 (hypercapnia and hypoxaemia).
    • Hypercapnia leads to respiratory acidosis
    • Hypoxaemia can lead to polycythemia (increased Hb) - leads to Cyanosis- BLUE Bloater
  • Hypoxaemia in alveolus initiates hypoxic pulmonary vasoconstriction - shunt to better ventilated alveoli
  • Increase in pulmonary vascular resistance can back blood up into the right side of the heart
  • R sided hypertrophy (Cor pulmonale) and heart failure
  • Reduced venous return to the left side of the heart
  • Reduced left ventricular output leading to activation of the RAAS system
  • Fluid retention and exacerbation of oedema - BLOATER
30
Q

Outline the gross pathology of emphysema/ Pink puffer

What clinical signs does this show as?

A
  • Exposure to smoke/ pollution—> activation of macrophages within alveolus
  • Activated macrophages releases proteases and cytokines—> recruitment of neutrophils
  • Neutrophils release elastase–> destruction elastin—> loss elastic recoil –> air trapping and hyperinflation and hypoventilation
  • Hypoventilation—> increased CO2 (hypercapnia) decreased O2 (hypoxia)
  • Hyperinflation—> barrel chest–> increased effort to breathe
  • Effort to breathe—> cachexia, dysponea, use of accessory muscles
  • Destruction of alveolar walls and pulmonary capillaries by proteases—> reduced perfusion
  • Matched defecit in V/Q
31
Q

What diagnostic sign will a patient with COPD show on spirometry?

What additional investigations could be done and what could they show?

A
  • Patient will show an decreased FEV1: FVC ratio- less than 0.7.
  • In COPD both FVC and FEV1 will decrease due to increased resistance of the airways but FEV1 will decrease more
  • FEV1 less than 80% of predicted
  • Chest xray could also be done which could show hyperinflation
  • FBC could be done- may show increased Hb (Polycythemia) as with chronic hypoxia.
32
Q

Outline the management plan COPD

A
  • SMOKING CESSATION- only way to prolong life expectancy
  • Bronchodilators:
    • Short acting B2 agonists- salbutamol/ terbutaline
    • Short acting anticholinergic- ipratroprium bromide
  • Combination therapy:
    • Long acting B2 agonist- Salmeterol/ formoterol PLUS inhaled corticosteroid (Fluticasone)
    • Long acting anticholinergic- Tiotroprium bromide
  • Home oxygen
  • Pulmonary rehabilitation programme and MDT management
  • Vaccinations: Pneumoccocal (prevent community acquired pneumonia) and annual influenza.
33
Q

Outline management of an acute exacerbation of COPD

A
  • Inhaler/ nebuliser B2 agonists and anticholingergic drugs
  • Oral steroid for 7 days- prednisilone
  • Antibiotics for infection
  • Non invasive ventilation